8-K current report · filed Nov 12, 2026

Olema Pharmaceuticals, Inc. (OLMA) 8-K Current Report: November 12, 2026

Item 5.03Item 7.01Item 8.01Item EX-99.1OLMA overview

Short answer

Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Corporate name changed from Olema Pharmaceuticals, Inc. to Olema Oncology, Inc. effective November 12, 2026.

Olema Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Corporate name changed from Olema Pharmaceuticals, Inc. to Olema Oncology, Inc. effective November 12, 2026
  • Name change required no stockholder approval, reducing execution friction
  • Common stock continues trading on Nasdaq Global Select Market under ticker OLMA
  • Amended bylaws updated to reflect the new corporate name

Item 7.01 · Regulation FD Disclosure

  • Olema Oncology announced a corporate name change on November 12, 2026
  • Name change may affect ticker, branding, investor communications and corporate records
  • Investors should review Exhibit 99.1 for the new name and implementation details

Item 8.01 · Other Events

  • Principal executive offices relocated effective November 12, 2026
  • New headquarters: 365 Oyster Point Blvd., Suite 400, South San Francisco, California
  • Administrative change with limited direct impact on operations or shareholder economics

Item EX-99.1 · Exhibit EX-99.1

  • Corporate name changed to Olema Oncology, Inc. effective November 12, 2026
  • Nasdaq listing and ticker unchanged: OLMA on the Nasdaq Global Select Market
  • No stockholder vote required, limiting immediate governance or ownership disruption
  • Rebranding emphasizes oncology focus as palazestrant advances through two Phase 3 trials
  • OP-3136 remains in Phase 1 development, extending the company’s pipeline beyond palazestrant

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Olema Pharmaceuticals, Inc. 8-K filings

Get the next OLMA 8-K as it lands

Follow OLMA for push alerts, or ask the research agent what this filing means.